Correlation Between Atea Pharmaceuticals and Immix Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Atea Pharmaceuticals and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Atea Pharmaceuticals and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Atea Pharmaceuticals and Immix Biopharma, you can compare the effects of market volatilities on Atea Pharmaceuticals and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Atea Pharmaceuticals with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Atea Pharmaceuticals and Immix Biopharma.

Diversification Opportunities for Atea Pharmaceuticals and Immix Biopharma

0.47
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Atea and Immix is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Atea Pharmaceuticals and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Atea Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Atea Pharmaceuticals are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Atea Pharmaceuticals i.e., Atea Pharmaceuticals and Immix Biopharma go up and down completely randomly.

Pair Corralation between Atea Pharmaceuticals and Immix Biopharma

Given the investment horizon of 90 days Atea Pharmaceuticals is expected to under-perform the Immix Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Atea Pharmaceuticals is 2.33 times less risky than Immix Biopharma. The stock trades about -0.02 of its potential returns per unit of risk. The Immix Biopharma is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  204.00  in Immix Biopharma on September 2, 2024 and sell it today you would earn a total of  7.00  from holding Immix Biopharma or generate 3.43% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Atea Pharmaceuticals  vs.  Immix Biopharma

 Performance 
       Timeline  
Atea Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Atea Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward indicators, Atea Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Immix Biopharma 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point.

Atea Pharmaceuticals and Immix Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Atea Pharmaceuticals and Immix Biopharma

The main advantage of trading using opposite Atea Pharmaceuticals and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Atea Pharmaceuticals position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.
The idea behind Atea Pharmaceuticals and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas